Hambach et al. used a CD38-specific Nb-CARs manufactured from NK-92 cells, which were effective against CD38-expressing multiple myeloma (MM) cell lines and primary patient-derived MM bone marrow samples [129]. This evidence concerns the gene CD38 and plasma cell myeloma.